Eton Pharmaceuticals Inc
NASDAQ:ETON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Eton Pharmaceuticals Inc
Cash from Investing Activities
Eton Pharmaceuticals Inc
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eton Pharmaceuticals Inc
NASDAQ:ETON
|
Cash from Investing Activities
-$333k
|
CAGR 3-Years
51%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Investing Activities
-$23.6B
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-12%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Investing Activities
-$4.1B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-10%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Investing Activities
-$1.4B
|
CAGR 3-Years
56%
|
CAGR 5-Years
21%
|
CAGR 10-Years
8%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Investing Activities
-$13.7B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Investing Activities
-$11B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
Eton Pharmaceuticals Inc
Glance View
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.
See Also
What is Eton Pharmaceuticals Inc's Cash from Investing Activities?
Cash from Investing Activities
-333k
USD
Based on the financial report for Dec 31, 2025, Eton Pharmaceuticals Inc's Cash from Investing Activities amounts to -333k USD.
What is Eton Pharmaceuticals Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-46%
Over the last year, the Cash from Investing Activities growth was 99%. The average annual Cash from Investing Activities growth rates for Eton Pharmaceuticals Inc have been 51% over the past three years , -46% over the past five years .
